Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085584 (
encephalopathy
)
18,178
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Microglial inflammation, involved in the occurrence and development of sepsis-associated
encephalopathy
, exhibits upregulation of proinflammatory cytokine and proinflammatory enzyme expression, leading to inflammation-induced neuronal cell apoptosis. TIR domain containing adaptor molecule-2 (TICAM-2) participates in lipopolysaccharide (LPS) mediated BV2 cell inflammation. SET8 plays a crucial role in a variety of cellular signal pathways. In this study, we hypothesize that SET8 participates in LPS-mediated microglial inflammation via modulation of TICAM-2 expression. Our data indicated that LPS induced BV2 inflammation via upregulation of TICAM-2 expression. Moreover, LPS treatment inhibited SET8 expression, while it increased
activating transcription factor 2
(
ATF2
) expression. The effects of sh-SET8 and
ATF2
overexpression were similar to that of LPS treatments. Inhibition of TICAM-2 expression counteracted sh-SET8-mediated and
ATF2
overexpression mediated BV2 cell inflammation. Further, SET8 was found to interact with
ATF2
. A mechanistic study found that H4K20me1, a downstream target of SET8, and
ATF2
enriched at the TICAM-2 promoter region. Luciferase reporter assays indicated that sh-SET8 increased TICAM-2 promoter activity but augmented the effect of
ATF2
overexpression on TICAM-2 promoter activity as well. Co-transfection of sh-SET8 with
ATF2
overexpression more dramatically increased TICAM-2 expression in BV2 cells. The present study indicated that SET8 interacted with
ATF2
to modulate TICAM-2 expression, which participated in LPS-mediated BV2 cell inflammation.
...
PMID:SET8 participates in lipopolysaccharide-mediated BV2 cell inflammation via modulation of TICAM-2 expression. 3217 60